Overview

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Atorvastatin
Atorvastatin Calcium
Krestin
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Healthy men and women between 21 to 60 years of age will be recruited to participate
in this study.

- Subjects will be eligible if metabolic, renal, hepatic, and hematological laboratory
tests are within normal limits.

Exclusion Criteria:

- Subjects will be excluded from the study if they have a current or past history of
cardiovascular, hepatic, endocrine (e.g., diabetes), renal, pancreatic,
gastrointestinal, pulmonary, immunologic, hematologic, or neurologic disease.